Quinazoline compounds of formula IB1 are described, along with their use as lysosomotropic agents against inflammation, fungi, unicellular parasitic microorganisms and cancer. The described compounds are useful for the treatment of diseases characterized by pathogenic cells featuring lysosomes or other acidic vacuoles with disease-related alterations predisposing them to accumulation of compounds of the invention, which then selectively inactivate or eliminate such pathogenic cells.
